Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Fabrizio Artioli(Roche (Switzerland)), Roberto D’Amico(University of Modena and Reggio Emilia), Daniele Generali(University of Trieste), Alberto Bottini(University of Genoa), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Giardina(Istituti Ospitalieri di Cremona), C. Boni(Ospedale Santa Maria), Patrizia Serra(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giancarlo Bisagni, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Laura Orlando, Alberto Ravaioli(Florence (Netherlands)), Michael Untch(Helios Kliniken), Luca Marini, M. Bagnalasta(GlaxoSmithKline (Netherlands))
Journal of Clinical Oncology
April 10, 2012
Cited by 368


Related Papers